Related references
Note: Only part of the references are listed.Polycomb Repressive Complex 2 Is a Barrier to KRAS-Driven Inflammation and Epithelial-Mesenchymal Transition in Non-Small-Cell Lung Cancer
Michela Serresi et al.
CANCER CELL (2016)
Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival
Arjen H. G. Cleven et al.
MODERN PATHOLOGY (2016)
A laminin 511 matrix is regulated by TAZ and functions as the ligand for the α6Bβ1 integrin to sustain breast cancer stem cells
Cheng Chang et al.
GENES & DEVELOPMENT (2015)
Transcriptional plasticity promotes primary and acquired resistance to BET inhibition
Philipp Rathert et al.
NATURE (2015)
Prolonged Ezh2 Depletion in Glioblastoma Causes a Robust Switch in Cell Fate Resulting in Tumor Progression
Nienke A. de Vries et al.
CELL REPORTS (2015)
The Methyltransferase EZH2 is not Required for Mammary Cancer Development, Although High EZH2 and Low H3K27me3 Correlate With Poor Prognosis of ER-Positive Breast Cancers
Woo Kyun Bae et al.
MOLECULAR CARCINOGENESIS (2015)
Inhibiting Enhancer of Zeste Homolog 2 Promotes Cellular Senescence in Gastric Cancer Cells SGC-7901 by Activation of p21 and p16
Jie Bai et al.
DNA AND CELL BIOLOGY (2014)
PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies
Thomas De Raedt et al.
NATURE (2014)
Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors
Ming Zhang et al.
NATURE GENETICS (2014)
PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors
William Lee et al.
NATURE GENETICS (2014)
A global assessment of cancer genomic alterations in epigenetic mechanisms
Muhammad A. Shah et al.
EPIGENETICS & CHROMATIN (2014)
EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21waf1/cip1 and by inhibiting mutant p53
Shelly Seward et al.
CANCER LETTERS (2013)
The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression
Kui-Ming Chan et al.
GENES & DEVELOPMENT (2013)
Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer
Christoph Plass et al.
NATURE REVIEWS GENETICS (2013)
Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma
Peter W. Lewis et al.
SCIENCE (2013)
EZH2-shRNA-mediated upregulation of p21waf1/cip1 and its transcriptional enhancers with concomitant downmodulation of mutant p53 in pancreatic ductal adenocarcinoma
Ramesh B. Batchu et al.
SURGERY (2013)
Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis
Srikanth Nagalla et al.
GENOME BIOLOGY (2013)
Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host
Winston Timp et al.
NATURE REVIEWS CANCER (2013)
Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms
Joannah Score et al.
BLOOD (2012)
Polycomb Protein EZH2 Regulates Tumor Invasion via the Transcriptional Repression of the Metastasis Suppressor RKIP in Breast and Prostate Cancer
Gang Ren et al.
CANCER RESEARCH (2012)
A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia
Camille Simon et al.
GENES & DEVELOPMENT (2012)
EZH2 couples pancreatic regeneration to neoplastic progression
Jon Mallen-St Clair et al.
GENES & DEVELOPMENT (2012)
Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes
Karolina Holm et al.
MOLECULAR ONCOLOGY (2012)
Approaching a state shift in Earth's biosphere
Anthony D. Barnosky et al.
NATURE (2012)
Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas
Gang Wu et al.
NATURE GENETICS (2012)
Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia
Panagiotis Ntziachristos et al.
NATURE MEDICINE (2012)
Silencing of Kruppel-like factor 2 by the histone methyltransferase EZH2 in human cancer
H. Taniguchi et al.
ONCOGENE (2012)
EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent
Kexin Xu et al.
SCIENCE (2012)
Histopathological variables and biomarkers enhancer of zeste homologue 2, Ki-67 and minichromosome maintenance protein 7 as prognosticators in primarily endocrine-treated prostate cancer
Teemu T. Tolonen et al.
BJU INTERNATIONAL (2011)
MYC enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and posttranscriptional mechanisms
Cheryl M. Koh et al.
CANCER RESEARCH (2011)
Context-Specific Regulation of NF-κB Target Gene Expression by EZH2 in Breast Cancers
Shuet Theng Lee et al.
MOLECULAR CELL (2011)
Most Random Gene Expression Signatures Are Significantly Associated with Breast Cancer Outcome
David Venet et al.
PLOS COMPUTATIONAL BIOLOGY (2011)
Integrative Genomic Profiling of Human Prostate Cancer
Barry S. Taylor et al.
CANCER CELL (2010)
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Thomas Ernst et al.
NATURE GENETICS (2010)
The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer
J. Yu et al.
ONCOGENE (2010)
Ezh2 Orchestrates Gene Expression for the Stepwise Differentiation of Tissue-Specific Stem Cells
Elena Ezhkova et al.
CELL (2009)
Ndy1/KDM2B immortalizes mouse embryonic fibroblasts by repressing the Ink4a/Arf locus
Alexandros Tzatsos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation
Satoshi Fujii et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers
Yongkun Wei et al.
MOLECULAR CARCINOGENESIS (2008)
Members of a family of JmjC domain-containing oncoproteins immortalize embryonic fibroblasts via a JmjC domain-dependent process
Raymond Pfau et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients
Sari Laitinen et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2
L. Beke et al.
ONCOGENE (2007)
The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells
Adrian P. Bracken et al.
GENES & DEVELOPMENT (2007)
EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast
IM Bachmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer
H Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer
AP Bracken et al.
EMBO JOURNAL (2003)
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells
CG Kleer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
The polycomb group protein EZH2 is involved in progression of prostate cancer
S Varambally et al.
NATURE (2002)
Share Paper
